Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 878 participants.
Also called NCT01676220
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 878 participants
- Sponsor
- Registry
-
NCT01676220 -
2012-000146-35
-
- Main results
- New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Lithuania, Netherlands, Puerto Rico, Romania, Slovakia, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT01676220. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2015-04-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
- Acronym
- EDITION III
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- HOE901-U300 (new formulation of insulin glargine)
- Intervention (Drug)
- Lantus (insulin glargine)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01676220- Content hash
d26dc73a56373128f1ca54ecdd6386653f2711eb14106e8f28dc6c49ee25379b